Additional Information

Description

BOTOX® Cosmetic (OnabotulinumtoxinA) is a sterile injection that comes as a vacuum-dried powder supplied in a single-dose vial for reconstitution. Each vial contains 100 Units of Clostridium botulinum type A neurotoxin complex, 0.9 mg of sodium chloride, and 0.5 mg of Albumin Human in a vacuum-dried form without a preservative. The purified botulinum toxin of type A present in the dried powder is produced via fermentation of Clostridium botulinum type A. The injection is administered through intradermal, intramuscular, and intradetrusor routes only.

BOTOX® Cosmetic (OnabotulinumtoxinA) is indicated in adults for temporarily improving the appearance of moderate to severe forehead lines linked to frontalis muscle activity. It is also used to improve lateral canthal lines in association with orbicularis oculi activity. Moreover, the BOTOX cosmetic is also indicated to improve glabellar lines associated with procerus muscle activity or corrugator. The injection is contraindicated in patients with a history of known hypersensitivity reaction towards botulinum toxin type A.

Additional Information

Description

BOTOX cosmetic (OnabotulinumtoxinA) is a sterile injection that comes as a vacuum dried powder supplied in a single-dose vial for reconstitution. Each vial contains 100 Units of Clostridium botulinum type A neurotoxin complex, 0.9 mg of sodium chloride and 0.5 mg of Albumin Human in a vacuum-dried form without a preservative. The purified botulinum toxin of type A present in the dried powder is produced via fermentation of clostridium botulinum type A. The injection is administered through intradermal, intramuscular and intradetrusor route only. BOTOX cosmetic (OnabotulinumtoxinA) is indicated in adults for temporarily improving the appearance of moderate to severe forehead lines linked to frontalis muscle activity. It is also used to improve lateral canthal lines in association with orbicularis oculi activity. Moreover, the BOTOX cosmetic is also indicated to improve glabellar lines associated with procerus muscle activity or corrugator. The cumulative dose must not exceed 400 units in an interval of 3 months. The injection is contraindicated in patients with a history of known hypersensitivity reaction towards botulinum toxin type A.